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Abstract
Multiple myeloma is a heterogeneous disease whose pathogenesis has not been completely elucidated. Although
B-cell receptors play a crucial role in myeloma pathogenesis, the impact of clonal immunoglobulin heavy-chain
features in the outcome has not been extensively explored. Here we present the characterization of complete heavy-
chain gene rearrangements in 413 myeloma patients treated in Spanish trials, including 113 patients characterized by
next-generation sequencing. Compared to the normal B-cell repertoire, gene selection was biased in myeloma, with
significant overrepresentation of IGHV3, IGHD2 and IGHD3, as well as IGHJ4 gene groups. Hypermutation was high in
our patients (median: 8.8%). Interestingly, regarding patients who are not candidates for transplantation, a high
hypermutation rate (≥7%) and the use of IGHD2 and IGHD3 groups were associated with improved prognostic features
and longer survival rates in the univariate analyses. Multivariate analysis revealed prolonged progression-free survival
rates for patients using IGHD2/IGHD3 groups (HR: 0.552, 95% CI: 0.361−0.845, p= 0.006), as well as prolonged overall
survival rates for patients with hypermutation ≥7% (HR: 0.291, 95% CI: 0.137−0.618, p= 0.001). Our results provide new
insights into the molecular characterization of multiple myeloma, highlighting the need to evaluate some of these
clonal rearrangement characteristics as new potential prognostic markers.
Introduction
B-cell lymphoproliferative disorders are caused by the
expansion of a pathological clone at a specific stage of
differentiation reflected in the B-cell receptor (BCR).
Through multiple, hierarchically structured events, BCR
genes from each B cell are assembled in a particular shape
that confers an extremely high diversity to the B-cell
repertoire to recognize different antigens1. IGHV, IGHD
and IGHJ immunoglobulin genes go through recombi-
nation during early B-cell ontogeny that takes place in the
bone marrow (BM), an entirely random, antigen-
independent process driven by the Recombination-
Activating Genes (RAG1 and RAG2)2 and Terminal
deoxynucleotidyl Transferase (TdT)3. In humans, there
are more than 50 IGHV genes, 27 IGHD genes and 6 IGHJ
genes. IGHV and IGHD genes are clustered into seven
different groups4. During B-cell differentiation, one allele
is rearranged to produce a complete heavy-chain rear-
rangement (IGH) with or without the rearrangement of
the second IGH allele5. This means that one or two IGH
rearrangements can be found in each individual B cell,
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although only one of them is expressed as a functional
protein6. Immunoglobulin-expressing B cells then migrate
to germinal centers to undergo two antigen-dependent
processes: somatic hypermutation (SHM) and class-
switch recombination (CSR)7.
As a clonal B-cell malignancy, multiple myeloma (MM)
arises from a single cell, that has been recognized as a
post-germinal center, IgA/IgG switched B cell in several
studies8. VDJH usage, Complementarity-determining
Region 3 (CDR3) composition and somatic hypermuta-
tion (SHM) levels have been studied for the vast majority
of B-cell malignancies, as well as for normal, healthy B
cells9–12. The most interesting finding to date is the close
association between SHM rate and the outcome in
chronic lymphocytic leukemia (CLL), since a high SHM
rate (>2%) is associated with good prognosis13. Another
interesting observation is the presence of stereotyped
immunoglobulin receptors, not only in CLL14 but also in
mantle-cell lymphoma (MCL) or marginal zone lym-
phoma (MZL), which led researchers to infer that this was
a common phenomenon for all mature B-cell tumors with
potential prognostic and therapeutic implications15. Sev-
eral studies performed with MM patients treated with
conventional chemotherapy did not find any correlation
between prognosis and VDJH gene usage, CDR3 amino
acid composition or SHM rates16–18. However, most
series often included an insufficient number of hetero-
geneously treated patients, which makes any conclusion
difficult to be inferred.
Here, we present the largest-to-date analysis of the
VDJH repertoire in multiple myeloma, consisting in bio-
logical and clinical data from 413 patients diagnosed and
treated according to the Spanish Myeloma Group (GEM-
PETHEMA) protocols. Data were used for a compre-
hensive investigation of VDJH rearrangement character-
istics, including IGHV, IGHD and IGHJ gene usage, SHM
level and distribution, or complementarity-determining
region (CDRs) and framework region (FWRs) length and
composition. We also tried to identify the presence of
potential clusters of stereotyped receptors, assessing




A total of 413 newly diagnosed MM patients, diag-
nosed from 1995 to 2016, were included in the present
study. Most of them, 319 (77%), were enrolled in
clinical trials from the GEM-PETHEMA Spanish MM
group: GEM200019 (NCT00560053, n= 27), GEM2005-
más6520 (NCT00443235, n= 23), GEM2005MENOS6521
(NCT00461747, n= 20), GEM2010MAS6522 (NCT01237249,
n= 83), QUIREDEX23 (NCT00480363, n= 29), GEM2012-
MENOS6524 (NCT01916252, n= 130) and GEM-CESAR25
(NCT00480363, n= 7). The 94 remaining patients were
treated following the same protocols (GEM2000,
GEM2005), but they were not formally included in any
clinical trial.
According to the International Myeloma Working
Group (IMWG) criteria26, patients with either t(4;14),
t(14;16) or del17p were grouped together as a high-risk
(HR) cytogenetics subset for subsequent analysis. Patients
with symptomatic myeloma were also stratified based on
the Revised International Staging System (R-ISS)27.
This study was approved by the Ethical Committee of
the University Hospital of Salamanca in accordance with
the Spanish law and the Declaration of Helsinki princi-
ples. Written informed consent was obtained from every
patient prior to the inclusion in each trial.
Sample collection and IGH sequencing
Genomic DNA was isolated from bone marrow aspi-
rates at the time of diagnosis using the automated DNA
Purification kit Maxwell® (Promega, Madison, WI, USA).
DNA quantification and quality assessment were done
using the NanoDrop2000 Spectrophotometer (Thermo-
Fisher, Waltham, MA, USA). For the amplification of
complete VDJH rearrangements, we used the BIOMED-2
(now Euroclonality©) FR1 primers28 in multiplexed PCR
reactions. All reactions were carried out in a 25 μL mix-
ture containing ~100 ng DNA and 10 μmol of each pri-
mer. Monoclonal assessment of amplified products was
carried out by GeneScanning using 1 μL of PCR reaction.
PCR products were sequenced in an automated ABI3500
XL DNA sequencer using Big-Dye terminators v3.1
(Applied Biosystems™, Foster City, CA, USA).
One hundred and thirteen samples were also analyzed
by next-generation sequencing (NGS) using the Lym-
phoTrack® methodology (Invivoscribe Technologies, San
Diego, CA, USA). We targeted the Framework Region 1
to amplify VDJH rearrangements from 113 patients. In
one-step PCR, amplicons were generated and indexed. A
purification step using Agentcourt AMPure XP
microbeads (Beckman Coulter Inc, Brea, CA, USA) was
performed; then, we assessed the quality of our amplicons
using the TapeStation 4200 (Agilent, Santa Clara, CA,
USA) and Qubit 2.0 (ThermoFisher, Waltham, MA,
USA). Libraries were sequenced in an MiSeq platform
(Illumina, San Diego, CA, USA) with 2 × 251 of read
length and aiming for 1 million reads per sample.
Immunophenotypic characterization
Patients were routinely characterized at diagnosis by
multiparametric flow cytometry. Bone marrow samples
were processed within 48 h after collection. Analysis was
performed using different assays, following the Euro-
Clonality/EuroFlow consortium guidelines: six-color
panel for six markers (CD38/CD138/CD45/CD19/CD56/
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CD117) in 78 patients, eight-color panel for eight markers
(CD38/CD138/CD45/CD19/CD56/CD117/CD27/CD81)
in the remaining 335 patients.
For data analysis, the values of all parameters measured
per tube were mathematically calculated for the individual
plasma-cell events using the merge and calculation
functions of the INFINICYT™ v2.0 software (Cytognos S.
L. Salamanca, Spain). Plasma cells were identified based
on the characteristic pattern of expression of CD38,
CD138, CD45 and light scatter features.
Sequence analysis
IGHV, IGHD and IGHJ genes from complete rearran-
gements detected using either Sanger or NGS were
identified comparing them with the IMGT/V-Quest
database29, taking into account the option for insertions/
deletions. Mutational status was assessed using the closest
germline gene. Sequences containing more than 2%
deviation from the germline were considered somatically
mutated, following previously described criteria13. Point
mutations were annotated, as well as the length and
composition of N-, P- and CDR3 regions.
FastQ files generated by deep sequencing were pro-
cessed using the LymphoTrackAnalysis® tool to retrieve
sequences from virtually every clonal B cell in the sam-
ples, allowing the identification of tumor clones if the
following criteria were met: (i) ≥20,000 total reads; (ii) at
least one but not more than 2 merged top reads ≥ 2.5% of
total reads and (iii) top first or second merged reads must
be at least twice more abundant than the third most
frequent read to be considered clonotypic.
Rearrangements were considered biallelic if the first two
reads met the aforementioned criteria, had similar read
count (less than 50% difference) and one was productive
while the other one unproductive. Moreover, rearrange-
ments were considered potentially biclonal if the first two
reads met the aforementioned criteria, had similar read
count (less than 50% difference) and both were
productive.
CDR3 clustering analysis
ClustalX2.0 was used as previously described30,31,
comparing CDR3 amino acid sequences obtained from
our cohort and 1117 additional sequences obtained from
the IMGT/LIGM-DB database32 corresponding to unique
rearrangements from both normal and human tumor
B cells.
Primary and secondary standard criteria31,33 were used as
described before to characterize immunoglobulin clusters.
Statistical analysis
Clinical and biological characteristics were analyzed
discriminating between transplant-eligible and noneligible
patients, as well as asymptomatic patients, with the SPSS
20.0 software (IBM, Armonk, NY, USA) using Fisher’s
exact test for discrete variables and the Mann−Whitney
test for continuous variables. The Kaplan–Meier method
and the log-rank test were used to plot and compare
progression-free survival (PFS) and overall survival (OS)
curves. Cox regression was used to perform the multi-
variate analysis. Receiver operating characteristic (ROC)
curves were used to evaluate potential cutoff values for
some variables. PFS was defined as the time from diag-
nosis to either disease progression, death or the last
follow-up visit. OS was defined as the time from diagnosis
to the last follow-up visit or decease. All reported p values
were obtained by a two-sided exact method, at the con-
ventional 5% significance level (p < 0.05).
Results
Clinical characteristics
Baseline characteristics of the 413 patients included in
the study are summarized in Table 1.
For transplant-eligible patients (n= 228), R-ISS stages I,
II and III represented 24.1%, 62.8% and 13.1% of this
subset, respectively. After induction, before the pre-
transplant conditioning regimen started, the overall
response ratio (ORR) was 92.4%: 15.3% were in stringent
complete response (sCR); 24.1% of patients had achieved
complete response (CR); and 26.5% of patients were in
very good partial response (VGPR). The remaining
patients were in partial response (PR, 26.5%). Median PFS
was 49.5 months; median OS was 67.9 months.
For transplant-ineligible patients (n= 149), R-ISS stages
I, II and III represented 13.1%, 77.9% and 9% of this
subgroup, respectively. After induction, the ORR was
89.7%: 7.7% were in sCR, 34.2% achieved CR, 14.5% were
in VGPR and 33.3% were in PR. Median PFS was
26.4 months; median OS was 57.7 months.
As expected, high-risk asymptomatic patients (n= 36)
were younger (median age: 60 years). Serum albumin
levels were higher (median: 3.76 g/dL) and β2 micro-
globulin levels were lower (median: 2.25 mg/L). Conse-
quently, 61.9% of smoldering patients were at ISS stage I,
and 38.1% were at stage II.
Detection of clonal VDJH gene rearrangements
Sanger sequencing allowed the identification of full
clonal VDJH gene rearrangements in 88% of patients
(363/413). In 23 cases, the clonal IGH gene rearrangement
was not detected, possibly due to a high polyclonal
background or lack of PCR amplification due to an
incorrect primer-annealing. In 12 cases, we could only
identify the IGHV gene, while in the remaining cases we
could identify two out of three genes (mostly IGHV and
IGHJ, but not IGHD, n= 13).
Combining Sanger and NGS, the overall VDJH detec-
tion rate was 92.5% (382/413). In all, 388 complete
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rearrangements were detected, including the identifica-
tion of five cases with a biallelic rearrangement, as well as
one case with a potential biclonal myeloma that was later
confirmed by flow cytometry (Fig. S1). Among them, 362
rearrangements (93.3%) were productive, while 26 rear-
rangements (6.7%) were unproductive (Fig. 1). Six of these
unproductive sequences corresponded to light-chain
myeloma patients.
Gene repertoire
IGHV, IGHD and IGHJ usage was identified in pro-
ductive rearrangements. Table 2 shows the frequencies of
IGHV gene group usage among the 362 productive rear-
rangements, with observed and expected frequencies
(based on the number of genes per IGHV group), as well
as SHM rates. No major differences were observed com-
paring transplant and nontransplant subgroups.










Men 54.5% 62.1% 45.8% 54.8%
Women 45.5% 37.9% 54.2% 45.2%
Age 64 years (37−91) 59 years (37−69) 72 years (48−91) 60 years (42−77)
IgH
IgG 59.4% 55.8% 62.8% 42.3%
IgA 32.8% 35.5% 30.4% 50%
Bence−Jones 6.9% 7.0% 6.8% 7.7%
Nonsecretory 0.9% 1.7% 0% 0%
IgL
Kappa chain 62.5% 63.5% 60.7% 50%
Lambda chain 37.5% 36.5% 39.3% 50%
Calcium 9.63 ± 1.72 mg/dL (0.45−17) 9.50 ± 1.99 mg/dL (0.45−17) 9.78 ± 1.37 mg/dL (2.28−14.4) 9.11 ± 0.49 mg/dL (8−10)
Creatinine 1.16 ± 0.84 mg/dL (0.20−6.50) 1.11 ± 0.76 mg/dL (0.20−6.50) 1.21 ± 0.93 mg/dL (0.36−5.90) 0.89 ± 0.28 mg/dL (0.50−1.61)
Albumin 3.52 ± 0.67 g/dL (1.43−5.50) 3.54 ± 0.73 g/dL (1.70−5.14) 3.51 ± 0.61 g/dL (1.43−5.50) 3.76 ± 0.46 g/dL (2.20−4.60)
β2 microglobulin 5.17 ± 5.22 mg/L (0−62) 5.11 ± 5.45 mg/L (0−62) 5.20 ± 4.98 mg/L (0.15−43.40) 2.25 ± 1.13 mg/L (0.30−4.41)
Hemoglobin 10.54 ± 1.98 g/dL (4.90−15.60) 10.55 ± 1.99 g/dL (5.50−15.50) 10.56 ± 1.97 g/dL (4.90−15.60) 12.38 ± 1.13 g/dL (10.10−14.70)
R-ISSa
Stage I 19.1% 24.1% 13.1% 61.9%
Stage II 69.7% 62.8% 77.9% 38.1%
Stage III 11.2% 13.1% 9.0% 0%
ECOG
0 23.8% 27.6% 20.3% 66.7%
1 49.7% 49.3% 50.7% 33.3%
2 20.2% 17.8% 21.6% 0%
3 4.0% 4.6% 3.4% 0%
4 2.3% 0.7% 4.1% 0%
Bone lesions
None 19.2% 19.7% 18.9% 100%
Minor lesions 42.1% 45.4% 38.5% 0%
Major lesions 38.7% 34.9% 42.7% 0%
Plasmacytoma 11.2% 14.1% 8.3% 0%
High LDH 15% 16.6% 13.3% 5.4%
t(11;14) 13.2% 7.4% 18.1% 3.4%
t(4;14) 11.7% 12.2% 9.4% 19.4%
t(14;16) 3% 4.6% 1% 6.9%
17p abnormalities 7% 7.1% 7.2% 4.3%
HR cytogenetics 20.3% 21.6% 16.5% 29.6%
1q gain 47.7% 46.4% 50% 26.3%
del1p 5.7% 7.2% 3% 20%
Clinical features were compared distinguishing between symptomatic (transplant-candidates and noncandidates) and smoldering myeloma patients.
IgH immunoglobulin heavy chain, IgL immunoglobulin light chain, R-ISS Revised International Staging System, ECOG Eastern Cooperative Oncology Group
Performance Status, LDH lactate dehydrogenase, HR cytogenetics high-risk cytogenetics.
aProportions of each ISS group are shown instead of the R-ISS for asymptomatic myeloma patients.
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IGHV genes
According to the IMGT criteria29,32, we detected 50
functional genes (Fig. S2 and Table S1) in our cohort.
Five canonical IGHV genes were never seen: IGHV1-45,
IGHV3-20, IGHV4-28, IGHV6-1 and IGHV7-04. Overall,
IGHV3-30 was the most abundant IGHV gene, with 46/
362 cases (12.7%), followed by IGHV3-33 (5.2%), IGHV3-
23 (5%) and IGHV1-69 (4.7%). On the other hand, some
IGHV genes usually rearranged in the normal B-cell
repertoire, such as IGHV3-20 or IGHV3-74, were
underrepresented or totally absent. Another interesting
finding was the presence of four cases using the IGHV4-
34 gene: two of them had high SHM rates (10 and 18.9%),
both were unproductive, and patients had light-chain
myeloma; the other two cases also showed higher SHM
rates than the mean (20.8 and 16.7%) and clonal rear-
rangements were productive. One of these patients had
light-chain myeloma while the other one was IgG
secretory MM.
Finally, we also found noncanonical, haplotype-dependent
IGHV genes in ten patients: IGHV4-30-2 (n= 1), IGHV4-
30-4 (n= 5), IGHV4-38-2 (n= 1) and IGHV5-10-1 (n= 3),
and one pseudogene (IGHV3-69-1, n= 1).
Compared to previous myeloma series, IGHV gene
frequencies in our cohort were similar with three excep-
tions (IGHV3-20, IGHV4-30-2 and IGHV6-1) that were
not found in our patients. We also observed that, while
IGHV3 gene group representation was similar between
both series, IGHV3-30 was overrepresented and IGHV3-
30-3 was underrepresented in our cohort.
IGHD and IGHJ genes
IGHD and IGHJ gene identification was assessed in 349/
362 sequences (96%).
IGHD3 and IGHD2 groups were the most abundant
(30.4% and 25.4%, respectively), with IGHD3-10 (10%) and
IGHD2-21 (8%) genes significantly overrepresented (p <
0.05) as compared to the expected value in healthy plasma
cells. Conversely, IGHD4-4 and IGHD6-25 were not found
in any sequence, and all members from the IGHD1 gene
group but IGHD1-26 seemed to be underrepresented (less
than 1.5% each one, Fig. S3 and Table S2). All these
Fig. 1 Study flowchart. From the starting population (n= 413), 92 patients were excluded. Hence, molecular profiling and survival analyses were
performed with 327/413 patients (79.2%).
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features were similar in previous myeloma series and were
also seen in other hematologic B-cell malignancies and in
normal plasma cells, although preference for IGHD2-21
was specially marked only in myeloma.
For IGHJ gene usage, we found a deep bias in the use of
certain genes matching previous observations concerning
different hematologic malignancies such as CLL, MCL,
and the normal bone marrow compartment: a significant
overrepresentation of IGHJ4 (46.4%) and IGHJ6 (25%) was
estimated (Fig. S4 and Table S3), while IGHJ2 and IGHJ1
were clearly underrepresented (2.9% and 1.1%, respec-
tively). However, we noticed that, compared to previous
series in myeloma, IGHJ4 was underrepresented and
IGHJ6 overrepresented. In addition, IGHJ1 and IGHJ6
usage in healthy plasma cells looked completely different
not only with respect to myeloma, but also with other
mature B-cell disorders.
We explored associations between VDJH repertoire and
risk factors. IGHJ6 gene group was more frequent among
patients with high-risk cytogenetics (37.9% vs. 17.8%, p=
0.025) considering only transplant-candidate patients.
IGHD1 gene group was also more frequently used by
patients harboring high-risk cytogenetics, although this
association was restricted to patients not candidates for
transplantation (41.7% vs. 13.2%, p= 0.026). However,
there were not relevant associations between the usage of
these genes and the outcome in terms of PFS or OS.
Transplant-eligible and -ineligible patients showed
similar proportions in VDJH gene usage (Table S4). In the
same line, high-risk smoldering patients did not show
significant differences in the use of VDJH genes compared
to symptomatic patients.
Somatic hypermutation rates and IGH composition
Somatic mutations could be correctly identified in
349 sequences: mutational load was high (mean: 9.2% ±
3.8; median: 8.8%; 95% CI: 8.8−9.6%; range: 0−22.7%),
with five cases showing more than 98% of homology with
germline genes. Comparing SHM rates between IGHV
groups, we found a significantly lower rate for IGHV2
Table 2 Group usage and SHM rates in IGHV genes.
IGHV group Expected frequency Observed frequency Median SHM % (95% CI)
IGHV1 10 (18.2%) 55 (15.2%) 10.0 (8.6–10.5)
IGHV2 3 (5.4%) 31 (8.6%) 6.5 (6.0–8.0)
IGHV3 26 (47.3%) 191 (52.7%) 8.8 (8.7–9.7)
IGHV4 12 (21.8%) 67 (18.5%) 9.2 (9.2–11.4)
IGHV5 2 (3.6%) 18 (5.0%) 7.2 (6.1–9.0)
IGHV6 1 (1.8%) 0 –
IGHV7 1 (1.8%) 0 –
Total 55 362 8.8 (8.8–9.6)
Comparison of SHM % Adjusted p value
IGHV1 vs. IGHV2 0.006
IGHV2 vs. IGHV4 0.001
IGHV2 vs. IGHV3 0.012
IGHV1 vs. IGHV5 0.301
IGHV4 vs. IGHV5 0.118
IGHV3 vs. IGHV5 0.790
IGHV1 vs. IGHV4 1
IGHV2 vs. IGHV5 1
IGHV3 vs. IGHV4 1
IGHV1 vs. IGHV3 1
The first two columns show the expected IGHV gene usage if all genes were randomly selected compared with the observed frequency within our cohort,
respectively. Observed and expected IGHV distributions were not different when the χ2 test was applied, demonstrating that there is no evidence of selection of
specific gene groups in myeloma. Median somatic hypermutation rates per IGHV group are shown on the right side of the table. Below, Kruskal−Wallis-based paired
comparisons are listed to determine potential differences in the hypermutation rate; a significantly lower mutation rate was found for patients using IGHV2 compared
to those using IGHV1 (p= 0.006), IGHV3 (p= 0.012) and IGHV4 (p= 0.001).
95% CI 95% confidence intervals.
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compared to IGHV1, IGHV3 and IGHV4 (Table 2).
Median SHM ratios of transplant-eligible and -ineligible
patients were similar (9.0% vs. 8.5% respectively, p=
0.869). Median SHM rate in symptomatic and asympto-
matic patients was also similar (9.0% vs. 8.8%, p= 0.845).
The complete sequence was available in 327/362 cases, so
we continued the analysis with this set (Fig. 1).
As far as the junction region was concerned, nucleotide
addition appeared in 92.5% of cases for the N1 region, and
in 88.6% of cases for the N2 region. Only three cases did
not show evidence of nucleotide addition, either in N1 or in
N2. Mean Guanine/Cytosine content of the N-regions was
58.8%. Evidence of exonuclease activity in at least one of
the two junction regions (IGHV-to-IGHD and/or IGHD-
to-IGHJ) was observed in all rearrangements, although
32.2% of cases displayed a fully conserved IGHV-3′ edge.
CDR3 amino acid composition
According to the IMGT numbering, we identified CDR3
positions (from amino acid 105 to amino acid 117).
Median CDR3 length was 15 amino acids (range 6−29);
this length was consistent across different myeloma sub-
groups (symptomatic, asymptomatic, transplant-eligible
and transplant-ineligible patients). Amino acid propor-
tions in myeloma were not significantly different from the
normal B-cell population (Fig. S5), with predominance of
Glycine, Alanine, Aspartic acid and Tyrosine.
Clustering analysis
CDR3 sequences from productive rearrangements (n=
362) were subjected to cluster analysis. We found one pair
from our cohort that showed more than 60% of amino
acid similarity. Consequently, and given they were clusters
not previously described, we applied the secondary cri-
teria. Although CDR3 lengths were similar (13 vs. 15
amino acids) and both rearrangements displayed the same
IGHJ4*02 germinal gene, IGHV and IGHD groups, as well
as IGHD reading frames, were not concordant. Thus, we
could not find any stereotyped immunoglobulin cluster
among these myeloma patients.
Impact of molecular variables on clinical outcomes
Considering patients with symptomatic myeloma, after
a median follow-up of 7.6 years (range 0.5−24.1), 120
patients had died; the majority of them (n= 76) were
transplant-ineligible. ROC curves showed that 7 and 8%
were the most optimal cutoffs for prognostic value of
SHM; optimal cutoffs for serum albumin (3.2 g/dL), β2
microglobulin (3.5 mg/dL), hemoglobin (9 g/dL) and
creatinine (1 mg/dL) were also estimated. In addition,
IGHD2 and IGHD3 users were grouped for subsequent
analyses, because they were the most common IGHD
groups and this bias has been observed in nearly every B-
cell malignancy9–18. Finally, all molecular data described
in previous paragraphs were combined with clinical data
to perform statistical comparisons in transplant-eligible
and -ineligible patients.
We first looked for relationships between treatment
response and molecular variables. No major associations
were seen, but two exceptions: (1) SHM ≥ 7% associated
with a higher rate of CR/sCR compared to patients with
SHM< 7% in the nontransplant subset (45.8% vs. 27.3%,
respectively; p= 0.026), and (2) IGHD3-3 usage was
associated with a better response in the transplant sub-
group (n= 10), since 80% of MM patients with an IGH
rearrangement choosing this particular gene achieved CR/
sCR vs. 36.8% for other IGHD genes (p= 0.019).
In addition, we detected that SHM rates were progres-
sively higher when symptomatic patients were analyzed
based on the differentiation stage of their pathologic
plasma cells: median SHM levels for CD19+/CD81+
(immature), CD19−/CD81+ (intermediate) and CD19
−/CD81− (mature) plasma-cell subsets were 7.0% (95%
CI: 5.2−11.4%), 8.50% (95% CI: 7.9−9.6%), and 9.3% (95%
CI: 9.1−10.2%), respectively (p= 0.029). Moreover, med-
ian PFS increased from intermediate to mature subgroups
(35.4 vs. 64.0 months respectively, p= 0.024) but not from
immature to intermediate subsets, probably because we
only found 11 CD19+/CD81+ cases in our series.
Transplant-ineligible patients
In the univariate analysis for PFS, improved survival of
transplant-ineligible patients was associated with 0−1
ECOG stages (p= 0.003), CR/sCR after the end of induc-
tion (p= 2 × 10−6), baseline hemoglobin ≥ 9 g/dL (p=
0.002), no use of the IGHD4 gene group (p= 0.036)
(Fig. 2a) or specifically the IGHD4-11 gene (p= 0.0003), use
of the IGHD2/IGHD3 gene groups (p= 0.012) (Fig. 2b), and
SHM rate ≥ 7% (p= 0.006) (Fig. 3a). Improved OS rates
were observed in the univariate analysis for those patients
with CR/sCR after induction (p= 0.00026), SHM rate ≥ 7%
(p= 0.00024) (Fig. 3b), standard-risk cytogenetics (p=
0.031) and serum hemoglobin ≥ 9 g/dL (p= 0.002).
One hundred and eleven transplant-ineligible patients
were included in the multivariate analysis. For PFS
(Table 3), CR/sCR achievement (p= 10−6, HR: 0.311,
95% CI: 0.196−0.494) and the use of IGHD2/IGHD3
gene groups (p= 0.006, HR: 0.552, 95% CI: 0.361
−0.845) appeared as independent prognostic factors of
prolonged survival rates. For OS, CR achievement after
induction retained its independent prognostic value for
improved survival probability (p= 0.010, HR: 0.347, 95%
CI: 0.154−0.780) as well as SHM ≥ 7% (p= 0.001, HR:
0.291, 95% CI: 0.137−0.618) and standard cytogenetic
risk (p= 0.016, HR: 0.369, 95% CI: 0.164−0.832).
Moreover, SHM rate was included in the multivariate
regression model not only as a discrete variable but also
as a continuous one to avoid potential bias induced with
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the cutoff selection of 7%; in this case, the variable
retained its prognostic value (p= 0.017, HR: 0.909, 95%
CI: 0.840−0.983) along with achieving CR/sCR and the
absence of cytogenetic risk, showing that an increment
of 1% in SHM reduces death risk by 9%.
Transplant-eligible patients
Univariate analysis for PFS showed improved outcomes
for patients in R-ISS stage I vs. II (p= 0.002) and III (p=
0.004), standard-risk cytogenetics (p= 3 × 10−6), 0−1
ECOG stages (p= 0.015), absence of 1q gains (p= 0.019)
and serum β2 microglobulin < 3.5mg/dL (p= 0.023). The
R-ISS stage (p= 6 × 10−6), high-risk cytogenetics (p= 4 ×
10-6), the ECOG score (p= 0.004), 1q gains (p= 0.016)
and serum β2 microglobulin (p= 0.002) also showed sig-
nificant associations with the OS in the same direction as
PFS. Interestingly, no molecular variable was significantly
associated with survival in this subset of patients.
One hundred and thirty-seven transplant-eligible
patients were included in the multivariate analysis.
Presence of 1q gains (p= 0.046, HR: 2.187, 95% CI:
1.015−4.714) and high-risk cytogenetics (p=
Fig. 3 Kaplan−Meier curves comparing PFS and OS for SHM subsets in transplant-ineligible patients. a Progression-free survival plot.
b Overall survival plot. Cases with more than 7% of SHM are represented in black, while cases with SHM below 7% are represented in red. Patients at
risk at each time point appear below each plot.
Fig. 2 Kaplan−Meier curves comparing PFS for IGHD4 and IGHD2/3 users in transplant-ineligible patients. Survival curves compare
progression-free survival rates between IGHD4 (a) or IGHD2/IGHD3 users (b) and other IGHD users. IGHD4 users are represented in red, while IGHD2/
IGHD3 users are represented in black in their respective plots. Patients at risk at each time point appear below each plot.
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0.000021, HR: 4.690, 95% CI: 2.267−9.700) were
associated with lower PFS rates. High-risk cytogenetics
retained its independent prognostic value for shorter
OS (p= 0.001, HR: 8.030, 95% CI: 2.406−26.809),
while serum β2 microglobulin levels < 3.5 mg/dL
associated with better outcomes (p= 0.039, HR: 0.116,
95% CI: 0.015−0.899).
Discussion
Here, we analyzed in depth the IGH locus, trying to
correlate its characteristics with clinical data in a large
cohort of 413 MM patients included in clinical trials.
VDJH usage description provided new insights into the
clonal differentiation and possible clinical implications for
MM, that could potentially improve patient care.
IGHV gene repertoire reflected its normal counterpart,
with IGHV3 being the predominant gene group. As in other
series, IGHV3 was overrepresented and IGHV1 under-
represented, although differences were not significant, with
a much less pronounced bias than that observed in
CLL12,13,31. Similarly, IGHV3-30, IGHV4-59 and IGHV4-
39 were overrepresented with respect to other IGHV
genes34–36, and although these genes are also common in
other lymphoproliferative disorders and normal plasma
cells, we noted that IGHV3-30 was specifically selected
only in myeloma. In contrast, IGHV3-23 and IGHV1-69
appeared to be less frequently selected in MM (≥8% of
representation in the normal B-cell population35,36 and B-
cell pathologies vs. ≤5% in our series).
IGHV4-34 representation is high in hematologic
malignancies such as B-ALL, CLL, MCL or diffuse large
B-cell lymphoma as well as in normal B cells9,11,31.
Interestingly, this gene is usually absent in the normal
plasma-cell population37, although it shows a wide
interindividual usage frequency38, and it is rarely selected
in MM17, but in this work it was not completely absent.
IGHV4-34 has been characterized as an inherently auto-
reactive antibody39,40 for it is widely represented in
autoimmune diseases (i.e. systemic lupus erythematosus).
Here, we found four clonal IGHV4-34 rearrangements;
they showed very high SHM rates and were usually
nonproductive, leading to light-chain myelomas. This
could be explained by the fact that during plasma-cell
differentiation, those cells displaying autoreactive-prone
Table 3 Univariate and multivariate analysis of clinical and biological factors influencing PFS and OS of transplant-
ineligible patients in our cohort.
Variable Univariate analysis for PFS Multivariate analysis for PFS Univariate analysis for OS Multivariate analysis for OS
Median survival p HR [95% CI] p Median survival p HR [95% CI] p
ECOG score
0−1 26.94 0.003 NS NS
2−4 21.35
Serum hemoglobin
<9 g/dL 14.03 0.001 NS 24.54 0.002 NS
≥9 g/dL 28.32 64.85
Post induction response
sCR/CR 49.35 0.008 0.311 [0.196−0.494] 1E−05 Not reached 0.00026 0.347 [0.154−0.780] 0.010
VGPR/PR 23.88 53.19
Cytogenetic risk
High risk 36.30 0.196 NS 78.59 0.031 0.369 [0.164−0.832] 0.016
Standard risk 25.03 39.95
IGHD4 usage
Yes 14.49 0.036 NS NS
No 27.96
IGHD4-11 usage
Yes 14.16 0.0003 NS NS
No 26.94
IGHD2 and IGHD3 usage
Yes 34.46 0.012 0.552 [0.361−0.845] 0.006 NS
No 23.46
SHM level
<7% 23.46 0.006 NS 34.73 0.00024 0.291 [0.137−0.618] 0.001
≥7% 26.45 64.85
Univariate analysis was first performed to evaluate the role of each clinical and biological variable described in this study. The table only shows statistically significant
variables that were later included in the multivariate analysis. Median survival is shown in months.
HR hazard ratio, CI confidence interval, NS nonsignificant.
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genes within their IGH rearrangements would be specially
targeted by the somatic hypermutation machinery, trying
to make them able to recognize only foreign antigens.
Moreover, in our series, two out of the three unproductive
rearrangements using VH1-69, another gene commonly
associated with autoimmune events, such as Thrombotic
Thrombocytopenic Purpura41, and highly represented in
CLL, were light-chain myelomas with some of the highest
SHM rates in our cohort (mean 12.23%). Interestingly,
this gene is commonly unmutated in CLL patients42,43.
SHM level was high and similar to what has been
observed in other studies for healthy and pathological
plasma and memory B cells. This would be in line with the
post-germinal center origin of myeloma8. A striking
finding was the presence of five MM cases with no
apparent SHM; however, the IGHV region could not be
completely sequenced (the entire FWR1 and part of the
FWR2 was missing); from our experience, we think the
mutational load was most likely underestimated, rather
than being truly unmutated cases.
CDR3 composition resembled the normal immunoglo-
bulin repertoire, with similar length, amino acid use, or
evidence of TdT and exonuclease activity44. This compo-
sition diverges from CLL, MCL or MZL patterns, where
restricted antibody sets account for approximately 30% of
cases45–47. Accordingly, cluster analysis failed to demon-
strate the presence of stereotyped receptors in our cohort,
as it has been shown before in myeloma patients48. Overall,
the gene repertoire in our series was very close to previous
reports17,18,48, although functional IGHV and IGHD genes,
whose use has not been reported in myeloma to date, have
been found in this cohort probably due to its larger size. On
the contrary, other genes such as IGHV1-18, IGHV3-20,
IGHV4-30-2 and IGHV6-1, found in Italian48 or Greek18
patients, are absent in Spanish patients, maybe reflecting
differences in the normal repertoire between different
Mediterranean subpopulations. No differences were
observed in the median length of the CDR3 region, and
somatic hypermutation was slightly higher than in previous
publications; however, this variation was not statistically
significant.
The most remarkable finding was the association between
a higher SHM level and an improved survival rate. The
explanation for this situation seems to be connected with
the maturation stage of tumor cells, represented by the
expression of CD19 and CD81 biomarkers, which is con-
sistent with previous findings regarding the immune profile
of tumor plasma cells:49 it suggests that early genetic
alterations in the ontogeny of germinal-center B cells would
provide a more aggressive profile in MM, which would be
strong enough to overcome SHM and/or CSR earlier.
Conversely, the acquisition of late, more harmless genetic
events would allow tumor B cells to undergo SHM and CSR
processes and this would lead to better outcomes. Another
possible explanation is related to the proliferation ratio of
tumor cells: highly proliferative B cells (and therefore, more
aggressive clones) activate DNA repair pathways that are
able to reduce the SHM level, as it has been shown in CLL
patients50,51. However, the SHM cutoff is based on FR1
primers; this threshold could differ when using leader
primers.
Another striking feature was the correlation between
the use of IGHD2 and IGHD3 gene groups and the out-
come. An increased usage of these particular groups has
also been observed in other series suggesting a positive
selective pressure over them8,17,18, since the bias was
observed only for complete rearrangements. Nevertheless,
whether or not the relationship between IGHD usage and
survival is a myeloma characteristic remains uncertain.
SHM and IGHD usage were associated with the out-
come only in the elderly, transplant-ineligible patients.
Thereby, the effect of intensive regimens could be the
main reason to explain why the negative prognostic
impact of these molecular characteristics is diluted in
younger, fit patients.
Regarding the value of clinical variables on the patient
outcome, the prognostic role of cytogenetics, hemoglobin,
albumin, β2 microglobulin and ECOG in MM was con-
firmed52. Cytogenetic risk has to be mentioned as this
variable showed significant associations with survival in all
cases but when applied to PFS in transplant-ineligible
patients. The absence of FISH studies for most patients
diagnosed from 1995 to 2000 (most of them being older)
made possible to find only 17 patients with high-risk cyto-
genetics in this subgroup, which could explain this result.
In conclusion, we have shown that multiple myeloma
plasma cells resemble the normal mature B-cell reper-
toire but, in contrast to CLL, MCL or MZL, stereotyped
receptors were absent14,15,53,54. Light-chain and non-
secretory myeloma cases could be explained by incor-
rect IGH rearrangements at the genomic DNA level, but
not always, which means that other effects could ham-
per the immunoglobulin production, including tran-
scriptional or translational defects. Finally, here, and for
the first time, we have reported how some molecular
characteristics of the IGH gene rearrangement, such as
higher SHM rates or IGHD2/IGHD3 gene usage, could
positively impact on the outcome of patients. A valida-
tion series is currently planned to elucidate whether
these findings could be applicable in real-life patients; if
validated in independent studies, they could be con-
sidered as new molecular markers for PFS and OS in
multiple myeloma.
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